Evidence map›Paper›PMID 40971868›Full record

ArticleJMIR formative research2025

Exploring the Role of Telemedicine in Duchenne Muscular Dystrophy: Benefits and Challenges.

Eliza Wasilewska, Andrzej Wasilewski, Alessandro Onofri, Jan Wasilewski, Dominika Sabiniewicz-Ziajka, Agnieszka Sobierajska-Rek, Jarosław Meyer-Szary, Karolina Śledzińska, Jolanta Wierzba, Marek Niedoszytko and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eliza WasilewskaDepartment of Allergology and Pulmonology, University Clinical Center Gdańsk (Accredited Duchenne Center), Medical University of Gdańsk, Gdansk, Poland.ORCID 0000-0002-5288-0586
Andrzej WasilewskiStudent Scientific Association of Medical Chemistry and Immunochemistry, Wroclaw Medical University, Wrocław, Poland.ORCID 0000-0001-9908-6921
Alessandro OnofriPediatric Pulmonology & Cystic Fibrosis Unit, Respiratory Intermediate Care Unit, Sleep and Long-Term Ventilation Unit, Bambino Gesù Children's Hospital, Scientific Institute for Research, Rome, Italy.ORCID 0000-0001-6527-0317
Jan WasilewskiRochester Institute of Technology, Rochester, NY, United States.ORCID 0000-0002-1990-9279
Dominika Sabiniewicz-ZiajkaDepartment of Rehabilitation, Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0002-9871-6183
Agnieszka Sobierajska-RekDepartment of Pediatric Cardiology, University Clinical Center (Accredited Duchenne Center), Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0002-3269-0646
Jarosław Meyer-SzaryDepartment of Pediatric Cardiology, University Clinical Center (Accredited Duchenne Center), Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0001-8791-5497
Karolina ŚledzińskaDepartment of Paediatrics, Haematology and Oncology, University Clinical Center (Accredited Duchenne Center), Medical University of Gdansk, Gdańsk, Poland.ORCID 0000-0001-6565-4572
Jolanta WierzbaDepartment of Paediatrics, Haematology and Oncology, University Clinical Center (Accredited Duchenne Center), Medical University of Gdansk, Gdańsk, Poland.ORCID 0000-0003-0290-1243
Marek NiedoszytkoDepartment of Allergology and Pulmonology, University Clinical Center Gdańsk (Accredited Duchenne Center), Medical University of Gdańsk, Gdansk, Poland.ORCID 0000-0003-1089-1911
Sylwia MałgorzewiczDepartment of Clinical Nutrition, University Clinical Center Gdańsk (Accredited Duchenne Center), Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0001-8773-9649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is the most frequent, progressive disease caused by a genetic defect that leads to the production of a nonfunctional form of dystrophin, thereby causing premature death. Ways to improve, adapt, and facilitate the care of people with DMD are still being explored. This viewpoint, developed by an accredited Duchenne center, aims to present current telemedicine options specifically tailored for patients with DMD and to discuss the advantages and limitations of these approaches across various health care domains. As one of the first centers in Poland to implement such an approach, the accredited Duchenne center provides targeted home-based care by using digital platforms and telemedicine tools. Additionally, we explore the potential of telemedicine to support different types of remote communication, including provider-to-provider, between patient/caregiver and provider, and between patient/caregiver and patient/caregiver interactions. This model has the potential to significantly enhance access to specialized care and improve the continuity and quality of life for those living with DMD.

Indexed as

Muscular Dystrophy, DuchenneTelemedicineCaregiversHumansPolandQuality of Lifedigital medicineDuchenne muscular dystrophyeHealthneuromuscular disorderstelemedicine

Identifiers

PMID40971868
PMCPMC12495364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.